Sneuro Medical

Based in Hangzhou, China and founded in 2018, Hangzhou Sneuro Medical Technology Co. , Ltd. , trading as Sneuro Medical, is a medical device company that focuses on the implantable neural stimulation and brain-computer interface field. The company owns more than 30 patents and has acquired a high-tech enterprise certificate and a Zhejiang Province technology-based small and medium-sized enterprise certificate.

Its spinal cord electrical stimulation system (SCS) completed its first implantation in January 2023. In March 2026, Sneuro Medical raised series C funding led by Legend Capital, with participation from SDIC Unity Capital, BioTrack Capital and OrbiMed Advisors. The company provides nerve stimulation products and treatment approaches for patients such as pain, epilepsy, and heart failure. It has developed three technology platforms: short-term implantation, rechargeable IPG, and wireless portability.

The product of the company includes three types of active nerve implantable medical devices, such as spinal cord nerve stimulator (SCS) and short-term implantable peripheral nerve electrical stimulation (PNS). The company generates revenue by providing nerve stimulation products and treatment approaches. The Series C funding raised in March 2026 will be primarily used to accelerate the innovation and iteration of the company's "ultra-miniature neuromodulation technology platform" and "brain-computer interface platform", as well as its global commercialization strategy.